We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01271426
First Posted: January 6, 2011
Last Update Posted: January 6, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Nihon University
  Purpose
To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.

Condition
Polypoidal Choroidal Vasculopathy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Association of Complement Factor H and ARMS2 Genotypes With Response of Polypoidal Choroidal Vasculopathy to Intravitreal Ranibizumab

Resource links provided by NLM:


Further study details as provided by Nihon University:

Primary Outcome Measures:
  • Association of Complement Factor H and ARMS2 Genotypes with Response of Polypoidal Choroidal Vasuculopathy to Intravitral Ranibizumab [ Time Frame: a month after injection ]

Biospecimen Retention:   Samples With DNA
white blood cell

Enrollment: 74
Study Start Date: April 2008
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
outpatients in hospital
Criteria

Inclusion Criteria:

  • Clinical diagnosis of Polypoidal choroidal vasculopathy
  • must have injection of Ranibizumab

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01271426


Locations
Japan
Surugadai Nihon university hospital
1-8-13 Kandasurugadai Chiyoda-ku, Tokyo, Japan, 101-8309
Sponsors and Collaborators
Nihon University
  More Information

ClinicalTrials.gov Identifier: NCT01271426     History of Changes
Other Study ID Numbers: NihonU-1
First Submitted: January 5, 2011
First Posted: January 6, 2011
Last Update Posted: January 6, 2011
Last Verified: January 2011

Keywords provided by Nihon University:
Polypoidal Choroidal Vasculopathy
Ranibizumab

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Ranibizumab
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents